State Street’s Trillium Therapeutics Inc. TRIL Stock Holding History

State Street’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,421,166	Closed	-$25M	–	4856
2021 Q3	$25M	Buy	1,421,166 +102,280	+8%	+$1.19M	﹤0.01%	2325
2021 Q2	$12.8M	Buy	+1,318,886	New	+$12.4M	﹤0.01%	2777

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

State Street's TRIL Position: Q4 2021 in Review

State Street sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,421,166 shares — an estimated $25M sold.

State Street first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $25M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

State Street reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
State Street sold 1,421,166 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $25M.
State Street first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
State Street's Trillium Therapeutics Inc. position peaked at $25M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on State Street's 13F filing for Q4 2021, filed 14 Feb 2022.